Skip to main content
SpringerLink
Log in

Quality-of-life assessment in clinical trials

  • Chapter
Recent Advances in Clinical Trial Design and Analysis

Part of the book series: Cancer Treatment and Research ((CTAR,volume 75))

Abstract

Within the context of clinical trials, quality of life (QOL) is a multidimensional concept that encompasses health-related constructs, but excludes other dimensions such as economics, housing, or education. Most QOL research has been based on the World Health Organization (WHO) definition of health [1]: ‘Health is not only the absence of infirmity and disease but also a state of physical, mental and social well-being.’ Thus QOL encompasses all health-related outcomes beyond those of survival and physiological responses. Diseases and their treatments affect not only patients’ physical functioning and level of pain, but also their cognitive, emotional, and social functioning. QOL measures have also included assessments of sexual functioning, family and marital relationships, role performance, vitality, sleep, health perceptions, general life satisfaction, and symptoms such as nausea and fatigue. QOL assessment has been employed in developing individual patient treatment plans, performing cost-benefit analyses, making health policy decisions, and conducting clinical trial evaluations. Health status, functional status, and health-related quality of life have become synonyms for QOL in the clinical trials literature.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Maguire P (1986). Using measures of psychological impact of disease to inform clinical practice. In Proceedings of the International Workshop on Quality of Life Assessment and Cancer Treatment, V Ventafridda, FSAM van Dam, R Yancik, M Tamburini (eds.). Amsterdam: Excerpta Medica, 119–126.

    Google Scholar 

  2. Slevin ML (1992). Quality of life: Philosophical question or a clinical reality. Br Med J 305:466–469.

    Article  CAS  Google Scholar 

  3. Weeks J (1992). Quality of life assessment: Performance status upstaged? J Clin Oncol 10:1827–1829.

    PubMed  CAS  Google Scholar 

  4. Laupacis A, Sackett DL, Roberts RS (1988). An assessment of clinically useful measurements of the consequences of treatment. N Engl J Med 318(26): 1728–1733.

    Article  PubMed  CAS  Google Scholar 

  5. Friedman LM, Furberg CD, Demets DL (1985). Fundamentals of Clinical Trials. Littleton, MA: PSG, 165.

    Google Scholar 

  6. Coates A, Gebski V, Signorini D, et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10:1833–1838.

    PubMed  CAS  Google Scholar 

  7. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948). The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634.

    Article  Google Scholar 

  8. Yates JW, Chalmer B, McKegney FP (1980). Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 45:2220–2224.

    Article  PubMed  CAS  Google Scholar 

  9. Zubrod CG, Schneiderman M, Frei E, et al. (1960). Appraisal of methods for the study of chemotherapy in man. J Chron Dis 11:7.

    Article  Google Scholar 

  10. Steinbroker O, Traeger CH, Battman RC (1949). Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662.

    Article  Google Scholar 

  11. Criteria Committee of the New York Heart Association, Kossman CE, chairman (1964). Diseases of the heart and blood vessels: Nomenclature and criteria for diagnosis, 6th edition. Boston: Little, 112–113.

    Google Scholar 

  12. Patterson WB (1975). The quality of survival in response to treatment. JAMA 233(3):280–281.

    Article  PubMed  CAS  Google Scholar 

  13. Izsak FC, Medalie JH (1971). Comprehensive follow-up of carcinoma patients. J Chron Dis 24:179–191.

    Article  PubMed  CAS  Google Scholar 

  14. Burge PS, Prankard TAJ, Richards JDM, et al. (1975). Quality of survival in acute myeloid leukemia. Lancet 2:621–624.

    Article  PubMed  CAS  Google Scholar 

  15. Priestman TJ, Baum M (1976). Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1:899–900.

    Article  PubMed  CAS  Google Scholar 

  16. Stewart AL, Hays RD, Ware JE Jr. (1988). The MOS short-form general health survey: reliability and validity in a patient population. Med Care 26:724.

    Article  PubMed  CAS  Google Scholar 

  17. Spitzer WO, Dobson AJ, Hall J, et al. (1981). Measuring the quality of life of cancer patients. J Chron Dis 34:585–597.

    Article  PubMed  CAS  Google Scholar 

  18. Franshel S, Bush JW (1970). A health state index and its application to health-services outcomes. Oper Res 18(6):1021–1066.

    Article  Google Scholar 

  19. Torrance GW, Thomas WH, Sackett DL (1972). A utility maximization model for evaluation of health care programs. Health Service Res 7:118.

    CAS  Google Scholar 

  20. Weinstein MC, Stason WB (1977). Foundations of cost-effective analysis for health and medical practices. N Engl J Med 296:716–721.

    Article  PubMed  CAS  Google Scholar 

  21. Levine MN, Guyatt GH, Gent M (1988). Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6(12): 1798–1810.

    PubMed  CAS  Google Scholar 

  22. Cella DF, Tulsky DS, Gray G, et al. (1993). The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579.

    PubMed  CAS  Google Scholar 

  23. Weeks JC, Kohane I, Hayes D (1994). Health-related quality of life data collection in routine clinical care using hand-held computers. A protocol submitted at the Dana-Farber Cancer Institute.

    Google Scholar 

  24. Presser S, Schuman H (1980). The measurement of a middle position in attitude surveys. Publ Opinion Q 44:70–85.

    Article  Google Scholar 

  25. Fayers PM, Jones DR (1983). Measuring and analyzing quality of life in cancer clinical trials: a review. Stat Med 2:429–446.

    Article  PubMed  CAS  Google Scholar 

  26. Kleinman A (1986). Social Origins of Distress and Disorder; Depression, Neurasthenia, and Pain in Modern China. New Haven: Yale University Press.

    Google Scholar 

  27. Guyatt GH, Feeny DH, Patrick DL (1993). Measuring health-related quality of life. Ann Intern Med 118(8): 622–629.

    PubMed  CAS  Google Scholar 

  28. Stewart AL (1990). Psychometric considerations in functional status instruments. In Functional Status Measurement in Primary Care, WONCA Classification Committee (eds.). New York: Springer-Verlag, 3–26

    Chapter  Google Scholar 

  29. Deyo RA, Diehr P, Patrick DL (1991). Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Controlled Clin Trials 12:142S–158S.

    Article  PubMed  CAS  Google Scholar 

  30. Cronbach LJ (1951). Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334.

    Article  Google Scholar 

  31. Ganz PA, Schag CAC, Lee JJ, et al. (1992). The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1:19–29.

    Article  PubMed  CAS  Google Scholar 

  32. Aaronson NK, Bullinger M, Ahmedzai S (1988). A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 111:231–249.

    Article  PubMed  CAS  Google Scholar 

  33. Schipper H, Clinch J, McMurray A, et al. (1984). Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 2:472–484.

    PubMed  CAS  Google Scholar 

  34. Hürny C, Bernhard J, Gelber RD, et al., for the International Breast Cancer Study Group (1992). Quality of life measures for patients receiving adjuvant therapy for breast cancer. Eur J Cancer 28:118–124.

    Article  PubMed  Google Scholar 

  35. Kirk RE (1968). Experimental Design: Procedures for the Behavioral Sciences. Belmont, CA: Brooks/Cole.

    Google Scholar 

  36. Olschewski M, Schumacher M (1990). Statistical analysis of quality of life data in cancer clinical trials. Stat Med 9:749–763.

    Article  PubMed  CAS  Google Scholar 

  37. Schumacher M, Olschewski M, Schulgen G (1991). Assessment of quality of life in clinical trials. Stat Med 10:1915–1930.

    Article  PubMed  CAS  Google Scholar 

  38. Cox DR, Fitzpatrick R, Fletcher AE, et al. (1992). Quality-of-life assessment: can we keep it simple? JR Stat Soc A 155(3):353–393.

    Article  Google Scholar 

  39. Nou E, Aberg T (1980). Quality of survival in patients with surgically treated bronchial carcinoma. Thorax 35:255–263.

    Article  PubMed  CAS  Google Scholar 

  40. Herson J (1980). Evaluation of toxicity: statistical considerations. Cancer Treat Rep 64:463–468.

    PubMed  CAS  Google Scholar 

  41. Rosenman J, Choi NC (1982). Improved quality of life in patients with small cell carcinoma of the lung by elective radiation of the brain. Int J Radiat Oncol 8:1040–1043.

    Article  Google Scholar 

  42. O’Brien PC (1984). Procedures for comparing samples with multiple endpoints. Biometrics 40:1079–1087.

    Article  PubMed  Google Scholar 

  43. Pocock SJ, Geller NL, Tsiatis AA (1987). The analysis of multiple endpoints in clinical trials. Biometrics 43:487–498.

    Article  PubMed  CAS  Google Scholar 

  44. Tandon PK (1990). Applications of global statistics in analyzing quality of life data. Stat Med 9:819–827.

    Article  PubMed  CAS  Google Scholar 

  45. Zwinderman AH (1990). The measurement of change of quality of life in clinical trials. Stat Med 9:931–942.

    Article  PubMed  CAS  Google Scholar 

  46. Gore S (1988). Integrated reporting of quality and length of life -A statistician’s perspective.Eur Heart J 9:228–234.

    PubMed  CAS  Google Scholar 

  47. Loewy JW, Kapadia AS, Hsi B, Davis BR (1992). Statistical methods that distinguish between attributes of assessment: prolongation of life versus quality of life. Med Decision Making 12:83–92.

    Article  CAS  Google Scholar 

  48. Lagakos SW, Sommer CJ, Zelen M (1978). Semi-Markov models for partially censored data. Biometrika 65(2):311–317.

    Article  Google Scholar 

  49. Silverstein MD, Albert DA, Hadler NM, Ropes MW (1988). Prognosis in SLE: comparison of Markov model to life table analysis. J Clin Epidemiol 41:623–633.

    Article  PubMed  CAS  Google Scholar 

  50. Levington A, Schulman J, Kammerman L, et al. (1980). A probability model of headache recurrence. J Chron Dis 53:407–412.

    Article  Google Scholar 

  51. Myers LE, Paulson DE, Berry WR, et al. (1980). A time-dependent statistical model which relates current clinical status to prognosis: application to advanced prostatic cancer. J Chron Dis 33:491–499.

    Article  PubMed  CAS  Google Scholar 

  52. Kay R (1986). A Markov model for analyzing cancer markers and disease states in survival studies. Biometrics 42:855–865.

    Article  PubMed  CAS  Google Scholar 

  53. Pepe MS, Longton G, Thornquist M (1991). A qualifier for the survival function to describe the prevalence of a transient condition. Stat Med 10:413–421.

    Article  PubMed  CAS  Google Scholar 

  54. Goldhirsch A, Gelber RD, Simes RJ, et al., for Ludwig Breast Cancer Study Group (1989). Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7:36–44.

    PubMed  CAS  Google Scholar 

  55. Feeny DH, Torrance GW (1989). Incorporating utility-based quality-of-life assessment measures in clinical trials. Med Care 27:S190–S204.

    Article  PubMed  CAS  Google Scholar 

  56. Gelber RD, Goldhirsch A (1986). A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772–1779.

    PubMed  CAS  Google Scholar 

  57. Gelber RD, Gelman RS, Goldhirsch A (1989). A quality of life oriented endpoint for treatment comparisons. Biometrics 45:781–795.

    Article  PubMed  CAS  Google Scholar 

  58. Glasziou PP, Simes RJ, Gelber RD (1990). Quality adjusted survival analysis. Stat Med 9:1259–1276.

    Article  PubMed  CAS  Google Scholar 

  59. Gelber RD, Goldhirsch A, Cavalli F, for the International Breast Cancer Study Group (1991). Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114:621–28.

    PubMed  CAS  Google Scholar 

  60. Gelber RD, Goldhirsch A, Hürny C, et al., for the International Breast Cancer Study Group (1992). Quality of life in clinical trials of adjuvant therapies. J Natl Cancer Inst Monogr 11:127–135.

    PubMed  Google Scholar 

  61. Gelber RD, Lenderking WR, Cotton DJ, et al., for the AIDS Clinical Trials Group (1992). Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 116:961–966.

    PubMed  CAS  Google Scholar 

  62. Lenderking WR, Gelber RD, Cotton DJ, et al. (1994). Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 330(11):738–743.

    Article  PubMed  CAS  Google Scholar 

  63. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 54:457–481.

    Article  Google Scholar 

  64. Volberding PA, Lagakos SW, Koch MA, et al. (1990). Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD-4 positive cells per cubic millimeter. N Engl J Med 322:941–949.

    Article  PubMed  CAS  Google Scholar 

  65. Weeks J, O’Leary J, Fairclough D, et al. (1994). The‘Q-tility index’: a new tool for assessing health-related quality of life and utilities in clinical trials and clinical practice. Proceedings of ASCO 13:436.

    Google Scholar 

  66. Gelber RD, Goldhirsch A, Cole BF, for the International Breast Cancer Study Group, (1993) Evaluation of effectiveness: Q-TWiST. Cancer Treat Rev 19:73–84.

    Article  PubMed  Google Scholar 

  67. Cole BF, Gelber RD, Goldhirsch A (1993). Cox regression models for quality adjusted survival analysis. Stat Med 12:975–987.

    Article  PubMed  CAS  Google Scholar 

  68. Gelber RD, Goldhirsch A, Cole BF, for the International Breast Cancer Study Group (1993). Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. Controlled Clin Trials 14:485–489.

    Article  PubMed  CAS  Google Scholar 

  69. Cole BF, Gelber RD, Anderson KM, for the International Breast Cancer Study Group (1994). Parametric approaches to quality adjusted survival analysis. Biometrics 50:621–631.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Richard D. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shari Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biomathematics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 237, Houston, Texas, 77030, USA

    Peter F. Thall Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gelber, R.D., Gelber, S. (1995). Quality-of-life assessment in clinical trials. In: Thall, P.F. (eds) Recent Advances in Clinical Trial Design and Analysis. Cancer Treatment and Research, vol 75. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2009-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2009-2_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5830-5

  • Online ISBN: 978-1-4615-2009-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation